BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note issued to investors on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $12.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $14.00.

BioCryst Pharmaceuticals Trading Down 0.2 %

NASDAQ BCRX opened at $5.26 on Tuesday. The firm’s 50 day simple moving average is $4.90 and its 200 day simple moving average is $5.45. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.46 and a beta of 1.96. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million for the quarter, compared to the consensus estimate of $85.62 million. During the same quarter in the previous year, the company earned ($0.28) earnings per share. The firm’s revenue for the quarter was up 34.9% on a year-over-year basis. On average, equities research analysts forecast that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Fifth Third Bancorp increased its stake in shares of BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,500 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 2,388 shares during the last quarter. Quarry LP acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $54,000. Tower Research Capital LLC TRC raised its stake in shares of BioCryst Pharmaceuticals by 131.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 5,912 shares during the last quarter. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth $64,000. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.